Meet with the ProSciento team of experts at the 58th European Association for the Study of Diabetes. Learn how our specialized expertise in the design and conduct of clinical trials for metabolic diseases can provide a competitive advantage for your first in human and early phase therapeutic or device programs.
Benefits of working with ProSciento:
- Conducted more phase I and II clinical trials for diabetes types 1 and 2, and NASH than any other U.S.-based provider
- 350+ Clinical trials completed in diabetes, NAFLD/NASH, and obesity
- Contributions to 17 approved metabolic drugs and devices
- 9+ Years as the leading metabolic clinical research provider